世界の副腎脊髄神経障害治療市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Adrenomyeloneuropathy Treatment Market Size, Status and Forecast 2021-2027

• レポートコード：QFJ1-3767
• 出版社/出版日：QYResearch / 2021年6月
※2024年版があります。お問い合わせください。
• レポート形態：英文、PDF、109ページ
• 納品方法：Eメール（納期：3日）
• 産業分類：医療

• 販売価格（消費税別）

Single User	￥577,200 (USD3,900)	▷ お問い合わせ
Multi User	￥865,800 (USD5,850)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

レポート概要

QYResearch社発行の本調査レポートでは、副腎脊髄神経障害治療の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（ステロイド補充療法、幹細胞移植）、用途別市場規模（病院、診療所、外来手術センター、その他）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、企業情報などをまとめております。
・市場概要
・副腎脊髄神経障害治療の市場動向
・企業の競争状況、市場シェア
・副腎脊髄神経障害治療の種類別市場規模と予測2016-2027（ステロイド補充療法、幹細胞移植）
・副腎脊髄神経障害治療の用途別市場規模と予測2016-2027（病院、診療所、外来手術センター、その他）
・副腎脊髄神経障害治療の北米市場規模2016-2027（アメリカ、カナダ）
・副腎脊髄神経障害治療の欧州市場規模2016-2027（ドイツ、フランス、イギリス等）
・副腎脊髄神経障害治療のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等）
・副腎脊髄神経障害治療の中南米市場規模2016-2027（メキシコ、ブラジル）
・副腎脊髄神経障害治療の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等）
・主要企業情報（Ascend Biopharmaceuticals、Novadip Biosciences、Eureka Therapeutics、Human Longevity、Regeneus、Allogene Therapeutics、BioRestorative Therapies、Immatics Biotechnologies、NewLink Genetics、Cytori Therapeutics、Talaris Therapeutics）
・結論

Market Analysis and Insights: Global Adrenomyeloneuropathy Treatment Market
The global Adrenomyeloneuropathy Treatment market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Adrenomyeloneuropathy Treatment market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Adrenomyeloneuropathy Treatment market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Adrenomyeloneuropathy Treatment market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Adrenomyeloneuropathy Treatment market.

Global Adrenomyeloneuropathy Treatment Scope and Market Size
Adrenomyeloneuropathy Treatment market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Adrenomyeloneuropathy Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Steroid Replacement Therapy
Stem Cell Transplant

Segment by Application
Hospitals
Clinics
Ambulatory Surgical Centers
Others

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Ascend Biopharmaceuticals
Novadip Biosciences
Eureka Therapeutics
Human Longevity
Regeneus
Allogene Therapeutics
BioRestorative Therapies
Immatics Biotechnologies
NewLink Genetics
Cytori Therapeutics
Talaris Therapeutics

レポート目次

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Adrenomyeloneuropathy Treatment Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Steroid Replacement Therapy
1.2.3 Stem Cell Transplant
1.3 Market by Application
1.3.1 Global Adrenomyeloneuropathy Treatment Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Ambulatory Surgical Centers
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Adrenomyeloneuropathy Treatment Market Perspective (2016-2027)
2.2 Adrenomyeloneuropathy Treatment Growth Trends by Regions
2.2.1 Adrenomyeloneuropathy Treatment Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Adrenomyeloneuropathy Treatment Historic Market Share by Regions (2016-2021)
2.2.3 Adrenomyeloneuropathy Treatment Forecasted Market Size by Regions (2022-2027)
2.3 Adrenomyeloneuropathy Treatment Industry Dynamic
2.3.1 Adrenomyeloneuropathy Treatment Market Trends
2.3.2 Adrenomyeloneuropathy Treatment Market Drivers
2.3.3 Adrenomyeloneuropathy Treatment Market Challenges
2.3.4 Adrenomyeloneuropathy Treatment Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Adrenomyeloneuropathy Treatment Players by Revenue
3.1.1 Global Top Adrenomyeloneuropathy Treatment Players by Revenue (2016-2021)
3.1.2 Global Adrenomyeloneuropathy Treatment Revenue Market Share by Players (2016-2021)
3.2 Global Adrenomyeloneuropathy Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Adrenomyeloneuropathy Treatment Revenue
3.4 Global Adrenomyeloneuropathy Treatment Market Concentration Ratio
3.4.1 Global Adrenomyeloneuropathy Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Adrenomyeloneuropathy Treatment Revenue in 2020
3.5 Adrenomyeloneuropathy Treatment Key Players Head office and Area Served
3.6 Key Players Adrenomyeloneuropathy Treatment Product Solution and Service
3.7 Date of Enter into Adrenomyeloneuropathy Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Adrenomyeloneuropathy Treatment Breakdown Data by Type
4.1 Global Adrenomyeloneuropathy Treatment Historic Market Size by Type (2016-2021)
4.2 Global Adrenomyeloneuropathy Treatment Forecasted Market Size by Type (2022-2027)

5 Adrenomyeloneuropathy Treatment Breakdown Data by Application
5.1 Global Adrenomyeloneuropathy Treatment Historic Market Size by Application (2016-2021)
5.2 Global Adrenomyeloneuropathy Treatment Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Adrenomyeloneuropathy Treatment Market Size (2016-2027)
6.2 North America Adrenomyeloneuropathy Treatment Market Size by Type
6.2.1 North America Adrenomyeloneuropathy Treatment Market Size by Type (2016-2021)
6.2.2 North America Adrenomyeloneuropathy Treatment Market Size by Type (2022-2027)
6.2.3 North America Adrenomyeloneuropathy Treatment Market Size by Type (2016-2027)
6.3 North America Adrenomyeloneuropathy Treatment Market Size by Application
6.3.1 North America Adrenomyeloneuropathy Treatment Market Size by Application (2016-2021)
6.3.2 North America Adrenomyeloneuropathy Treatment Market Size by Application (2022-2027)
6.3.3 North America Adrenomyeloneuropathy Treatment Market Size by Application (2016-2027)
6.4 North America Adrenomyeloneuropathy Treatment Market Size by Country
6.4.1 North America Adrenomyeloneuropathy Treatment Market Size by Country (2016-2021)
6.4.2 North America Adrenomyeloneuropathy Treatment Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada

7 Europe
7.1 Europe Adrenomyeloneuropathy Treatment Market Size (2016-2027)
7.2 Europe Adrenomyeloneuropathy Treatment Market Size by Type
7.2.1 Europe Adrenomyeloneuropathy Treatment Market Size by Type (2016-2021)
7.2.2 Europe Adrenomyeloneuropathy Treatment Market Size by Type (2022-2027)
7.2.3 Europe Adrenomyeloneuropathy Treatment Market Size by Type (2016-2027)
7.3 Europe Adrenomyeloneuropathy Treatment Market Size by Application
7.3.1 Europe Adrenomyeloneuropathy Treatment Market Size by Application (2016-2021)
7.3.2 Europe Adrenomyeloneuropathy Treatment Market Size by Application (2022-2027)
7.3.3 Europe Adrenomyeloneuropathy Treatment Market Size by Application (2016-2027)
7.4 Europe Adrenomyeloneuropathy Treatment Market Size by Country
7.4.1 Europe Adrenomyeloneuropathy Treatment Market Size by Country (2016-2021)
7.4.2 Europe Adrenomyeloneuropathy Treatment Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Adrenomyeloneuropathy Treatment Market Size (2016-2027)
8.2 Asia-Pacific Adrenomyeloneuropathy Treatment Market Size by Type
8.2.1 Asia-Pacific Adrenomyeloneuropathy Treatment Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Adrenomyeloneuropathy Treatment Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Adrenomyeloneuropathy Treatment Market Size by Type (2016-2027)
8.3 Asia-Pacific Adrenomyeloneuropathy Treatment Market Size by Application
8.3.1 Asia-Pacific Adrenomyeloneuropathy Treatment Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Adrenomyeloneuropathy Treatment Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Adrenomyeloneuropathy Treatment Market Size by Application (2016-2027)
8.4 Asia-Pacific Adrenomyeloneuropathy Treatment Market Size by Region
8.4.1 Asia-Pacific Adrenomyeloneuropathy Treatment Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Adrenomyeloneuropathy Treatment Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Adrenomyeloneuropathy Treatment Market Size (2016-2027)
9.2 Latin America Adrenomyeloneuropathy Treatment Market Size by Type
9.2.1 Latin America Adrenomyeloneuropathy Treatment Market Size by Type (2016-2021)
9.2.2 Latin America Adrenomyeloneuropathy Treatment Market Size by Type (2022-2027)
9.2.3 Latin America Adrenomyeloneuropathy Treatment Market Size by Type (2016-2027)
9.3 Latin America Adrenomyeloneuropathy Treatment Market Size by Application
9.3.1 Latin America Adrenomyeloneuropathy Treatment Market Size by Application (2016-2021)
9.3.2 Latin America Adrenomyeloneuropathy Treatment Market Size by Application (2022-2027)
9.3.3 Latin America Adrenomyeloneuropathy Treatment Market Size by Application (2016-2027)
9.4 Latin America Adrenomyeloneuropathy Treatment Market Size by Country
9.4.1 Latin America Adrenomyeloneuropathy Treatment Market Size by Country (2016-2021)
9.4.2 Latin America Adrenomyeloneuropathy Treatment Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Adrenomyeloneuropathy Treatment Market Size (2016-2027)
10.2 Middle East & Africa Adrenomyeloneuropathy Treatment Market Size by Type
10.2.1 Middle East & Africa Adrenomyeloneuropathy Treatment Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Adrenomyeloneuropathy Treatment Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Adrenomyeloneuropathy Treatment Market Size by Type (2016-2027)
10.3 Middle East & Africa Adrenomyeloneuropathy Treatment Market Size by Application
10.3.1 Middle East & Africa Adrenomyeloneuropathy Treatment Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Adrenomyeloneuropathy Treatment Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Adrenomyeloneuropathy Treatment Market Size by Application (2016-2027)
10.4 Middle East & Africa Adrenomyeloneuropathy Treatment Market Size by Country
10.4.1 Middle East & Africa Adrenomyeloneuropathy Treatment Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Adrenomyeloneuropathy Treatment Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Ascend Biopharmaceuticals
11.1.1 Ascend Biopharmaceuticals Company Details
11.1.2 Ascend Biopharmaceuticals Business Overview
11.1.3 Ascend Biopharmaceuticals Adrenomyeloneuropathy Treatment Introduction
11.1.4 Ascend Biopharmaceuticals Revenue in Adrenomyeloneuropathy Treatment Business (2016-2021)
11.1.5 Ascend Biopharmaceuticals Recent Development
11.2 Novadip Biosciences
11.2.1 Novadip Biosciences Company Details
11.2.2 Novadip Biosciences Business Overview
11.2.3 Novadip Biosciences Adrenomyeloneuropathy Treatment Introduction
11.2.4 Novadip Biosciences Revenue in Adrenomyeloneuropathy Treatment Business (2016-2021)
11.2.5 Novadip Biosciences Recent Development
11.3 Eureka Therapeutics
11.3.1 Eureka Therapeutics Company Details
11.3.2 Eureka Therapeutics Business Overview
11.3.3 Eureka Therapeutics Adrenomyeloneuropathy Treatment Introduction
11.3.4 Eureka Therapeutics Revenue in Adrenomyeloneuropathy Treatment Business (2016-2021)
11.3.5 Eureka Therapeutics Recent Development
11.4 Human Longevity
11.4.1 Human Longevity Company Details
11.4.2 Human Longevity Business Overview
11.4.3 Human Longevity Adrenomyeloneuropathy Treatment Introduction
11.4.4 Human Longevity Revenue in Adrenomyeloneuropathy Treatment Business (2016-2021)
11.4.5 Human Longevity Recent Development
11.5 Regeneus
11.5.1 Regeneus Company Details
11.5.2 Regeneus Business Overview
11.5.3 Regeneus Adrenomyeloneuropathy Treatment Introduction
11.5.4 Regeneus Revenue in Adrenomyeloneuropathy Treatment Business (2016-2021)
11.5.5 Regeneus Recent Development
11.6 Allogene Therapeutics
11.6.1 Allogene Therapeutics Company Details
11.6.2 Allogene Therapeutics Business Overview
11.6.3 Allogene Therapeutics Adrenomyeloneuropathy Treatment Introduction
11.6.4 Allogene Therapeutics Revenue in Adrenomyeloneuropathy Treatment Business (2016-2021)
11.6.5 Allogene Therapeutics Recent Development
11.7 BioRestorative Therapies
11.7.1 BioRestorative Therapies Company Details
11.7.2 BioRestorative Therapies Business Overview
11.7.3 BioRestorative Therapies Adrenomyeloneuropathy Treatment Introduction
11.7.4 BioRestorative Therapies Revenue in Adrenomyeloneuropathy Treatment Business (2016-2021)
11.7.5 BioRestorative Therapies Recent Development
11.8 Immatics Biotechnologies
11.8.1 Immatics Biotechnologies Company Details
11.8.2 Immatics Biotechnologies Business Overview
11.8.3 Immatics Biotechnologies Adrenomyeloneuropathy Treatment Introduction
11.8.4 Immatics Biotechnologies Revenue in Adrenomyeloneuropathy Treatment Business (2016-2021)
11.8.5 Immatics Biotechnologies Recent Development
11.9 NewLink Genetics
11.9.1 NewLink Genetics Company Details
11.9.2 NewLink Genetics Business Overview
11.9.3 NewLink Genetics Adrenomyeloneuropathy Treatment Introduction
11.9.4 NewLink Genetics Revenue in Adrenomyeloneuropathy Treatment Business (2016-2021)
11.9.5 NewLink Genetics Recent Development
11.10 Cytori Therapeutics
11.10.1 Cytori Therapeutics Company Details
11.10.2 Cytori Therapeutics Business Overview
11.10.3 Cytori Therapeutics Adrenomyeloneuropathy Treatment Introduction
11.10.4 Cytori Therapeutics Revenue in Adrenomyeloneuropathy Treatment Business (2016-2021)
11.10.5 Cytori Therapeutics Recent Development
11.11 Talaris Therapeutics
11.11.1 Talaris Therapeutics Company Details
11.11.2 Talaris Therapeutics Business Overview
11.11.3 Talaris Therapeutics Adrenomyeloneuropathy Treatment Introduction
11.11.4 Talaris Therapeutics Revenue in Adrenomyeloneuropathy Treatment Business (2016-2021)
11.11.5 Talaris Therapeutics Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Adrenomyeloneuropathy Treatment Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Steroid Replacement Therapy
Table 3. Key Players of Stem Cell Transplant
Table 4. Global Adrenomyeloneuropathy Treatment Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 5. Global Adrenomyeloneuropathy Treatment Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 6. Global Adrenomyeloneuropathy Treatment Market Size by Regions (2016-2021) & (US$ Million)
Table 7. Global Adrenomyeloneuropathy Treatment Market Share by Regions (2016-2021)
Table 8. Global Adrenomyeloneuropathy Treatment Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 9. Global Adrenomyeloneuropathy Treatment Market Share by Regions (2022-2027)
Table 10. Adrenomyeloneuropathy Treatment Market Trends
Table 11. Adrenomyeloneuropathy Treatment Market Drivers
Table 12. Adrenomyeloneuropathy Treatment Market Challenges
Table 13. Adrenomyeloneuropathy Treatment Market Restraints
Table 14. Global Adrenomyeloneuropathy Treatment Revenue by Players (2016-2021) & (US$ Million)
Table 15. Global Adrenomyeloneuropathy Treatment Market Share by Players (2016-2021)
Table 16. Global Top Adrenomyeloneuropathy Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Adrenomyeloneuropathy Treatment as of 2020)
Table 17. Ranking of Global Top Adrenomyeloneuropathy Treatment Companies by Revenue (US$ Million) in 2020
Table 18. Global 5 Largest Players Market Share by Adrenomyeloneuropathy Treatment Revenue (CR5 and HHI) & (2016-2021)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Adrenomyeloneuropathy Treatment Product Solution and Service
Table 21. Date of Enter into Adrenomyeloneuropathy Treatment Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Adrenomyeloneuropathy Treatment Market Size by Type (2016-2021) (US$ Million)
Table 24. Global Adrenomyeloneuropathy Treatment Revenue Market Share by Type (2016-2021)
Table 25. Global Adrenomyeloneuropathy Treatment Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 26. Global Adrenomyeloneuropathy Treatment Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 27. Global Adrenomyeloneuropathy Treatment Market Size Share by Application (2016-2021) & (US$ Million)
Table 28. Global Adrenomyeloneuropathy Treatment Revenue Market Share by Application (2016-2021)
Table 29. Global Adrenomyeloneuropathy Treatment Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 30. Global Adrenomyeloneuropathy Treatment Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 31. North America Adrenomyeloneuropathy Treatment Market Size by Type (2016-2021) (US$ Million)
Table 32. North America Adrenomyeloneuropathy Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 33. North America Adrenomyeloneuropathy Treatment Market Size by Application (2016-2021) (US$ Million)
Table 34. North America Adrenomyeloneuropathy Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 35. North America Adrenomyeloneuropathy Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 36. North America Adrenomyeloneuropathy Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 37. Europe Adrenomyeloneuropathy Treatment Market Size by Type (2016-2021) (US$ Million)
Table 38. Europe Adrenomyeloneuropathy Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 39. Europe Adrenomyeloneuropathy Treatment Market Size by Application (2016-2021) (US$ Million)
Table 40. Europe Adrenomyeloneuropathy Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 41. Europe Adrenomyeloneuropathy Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 42. Europe Adrenomyeloneuropathy Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 43. Asia-Pacific Adrenomyeloneuropathy Treatment Market Size by Type (2016-2021) (US$ Million)
Table 44. Asia-Pacific Adrenomyeloneuropathy Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 45. Asia-Pacific Adrenomyeloneuropathy Treatment Market Size by Application (2016-2021) (US$ Million)
Table 46. Asia-Pacific Adrenomyeloneuropathy Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 47. Asia-Pacific Adrenomyeloneuropathy Treatment Market Size by Region (2016-2021) & (US$ Million)
Table 48. Asia-Pacific Adrenomyeloneuropathy Treatment Market Size by Region (2022-2027) & (US$ Million)
Table 49. Latin America Adrenomyeloneuropathy Treatment Market Size by Type (2016-2021) (US$ Million)
Table 50. Latin America Adrenomyeloneuropathy Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 51. Latin America Adrenomyeloneuropathy Treatment Market Size by Application (2016-2021) (US$ Million)
Table 52. Latin America Adrenomyeloneuropathy Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 53. Latin America Adrenomyeloneuropathy Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 54. Latin America Adrenomyeloneuropathy Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 55. Middle East & Africa Adrenomyeloneuropathy Treatment Market Size by Type (2016-2021) (US$ Million)
Table 56. Middle East & Africa Adrenomyeloneuropathy Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 57. Middle East & Africa Adrenomyeloneuropathy Treatment Market Size by Application (2016-2021) (US$ Million)
Table 58. Middle East & Africa Adrenomyeloneuropathy Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 59. Middle East & Africa Adrenomyeloneuropathy Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 60. Middle East & Africa Adrenomyeloneuropathy Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 61. Ascend Biopharmaceuticals Company Details
Table 62. Ascend Biopharmaceuticals Business Overview
Table 63. Ascend Biopharmaceuticals Adrenomyeloneuropathy Treatment Product
Table 64. Ascend Biopharmaceuticals Revenue in Adrenomyeloneuropathy Treatment Business (2016-2021) & (US$ Million)
Table 65. Ascend Biopharmaceuticals Recent Development
Table 66. Novadip Biosciences Company Details
Table 67. Novadip Biosciences Business Overview
Table 68. Novadip Biosciences Adrenomyeloneuropathy Treatment Product
Table 69. Novadip Biosciences Revenue in Adrenomyeloneuropathy Treatment Business (2016-2021) & (US$ Million)
Table 70. Novadip Biosciences Recent Development
Table 71. Eureka Therapeutics Company Details
Table 72. Eureka Therapeutics Business Overview
Table 73. Eureka Therapeutics Adrenomyeloneuropathy Treatment Product
Table 74. Eureka Therapeutics Revenue in Adrenomyeloneuropathy Treatment Business (2016-2021) & (US$ Million)
Table 75. Eureka Therapeutics Recent Development
Table 76. Human Longevity Company Details
Table 77. Human Longevity Business Overview
Table 78. Human Longevity Adrenomyeloneuropathy Treatment Product
Table 79. Human Longevity Revenue in Adrenomyeloneuropathy Treatment Business (2016-2021) & (US$ Million)
Table 80. Human Longevity Recent Development
Table 81. Regeneus Company Details
Table 82. Regeneus Business Overview
Table 83. Regeneus Adrenomyeloneuropathy Treatment Product
Table 84. Regeneus Revenue in Adrenomyeloneuropathy Treatment Business (2016-2021) & (US$ Million)
Table 85. Regeneus Recent Development
Table 86. Allogene Therapeutics Company Details
Table 87. Allogene Therapeutics Business Overview
Table 88. Allogene Therapeutics Adrenomyeloneuropathy Treatment Product
Table 89. Allogene Therapeutics Revenue in Adrenomyeloneuropathy Treatment Business (2016-2021) & (US$ Million)
Table 90. Allogene Therapeutics Recent Development
Table 91. BioRestorative Therapies Company Details
Table 92. BioRestorative Therapies Business Overview
Table 93. BioRestorative Therapies Adrenomyeloneuropathy Treatment Product
Table 94. BioRestorative Therapies Revenue in Adrenomyeloneuropathy Treatment Business (2016-2021) & (US$ Million)
Table 95. BioRestorative Therapies Recent Development
Table 96. Immatics Biotechnologies Company Details
Table 97. Immatics Biotechnologies Business Overview
Table 98. Immatics Biotechnologies Revenue in Adrenomyeloneuropathy Treatment Business (2016-2021) & (US$ Million)
Table 99. Immatics Biotechnologies Recent Development
Table 100. NewLink Genetics Company Details
Table 101. NewLink Genetics Business Overview
Table 102. NewLink Genetics Adrenomyeloneuropathy Treatment Product
Table 103. NewLink Genetics Revenue in Adrenomyeloneuropathy Treatment Business (2016-2021) & (US$ Million)
Table 104. NewLink Genetics Recent Development
Table 105. Cytori Therapeutics Company Details
Table 106. Cytori Therapeutics Business Overview
Table 107. Cytori Therapeutics Adrenomyeloneuropathy Treatment Product
Table 108. Cytori Therapeutics Revenue in Adrenomyeloneuropathy Treatment Business (2016-2021) & (US$ Million)
Table 109. Cytori Therapeutics Recent Development
Table 110. Talaris Therapeutics Company Details
Table 111. Talaris Therapeutics Business Overview
Table 112. Talaris Therapeutics Adrenomyeloneuropathy Treatment Product
Table 113. Talaris Therapeutics Revenue in Adrenomyeloneuropathy Treatment Business (2016-2021) & (US$ Million)
Table 114. Talaris Therapeutics Recent Development
Table 115. Research Programs/Design for This Report
Table 116. Key Data Information from Secondary Sources
Table 117. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Adrenomyeloneuropathy Treatment Market Share by Type: 2020 VS 2027
Figure 2. Steroid Replacement Therapy Features
Figure 3. Stem Cell Transplant Features
Figure 4. Global Adrenomyeloneuropathy Treatment Market Share by Application: 2020 VS 2027
Figure 5. Hospitals Case Studies
Figure 6. Clinics Case Studies
Figure 7. Ambulatory Surgical Centers Case Studies
Figure 8. Others Case Studies
Figure 9. Adrenomyeloneuropathy Treatment Report Years Considered
Figure 10. Global Adrenomyeloneuropathy Treatment Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 11. Global Adrenomyeloneuropathy Treatment Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 12. Global Adrenomyeloneuropathy Treatment Market Share by Regions: 2020 VS 2027
Figure 13. Global Adrenomyeloneuropathy Treatment Market Share by Regions (2022-2027)
Figure 14. Global Adrenomyeloneuropathy Treatment Market Share by Players in 2020
Figure 15. Global Top Adrenomyeloneuropathy Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Adrenomyeloneuropathy Treatment as of 2020
Figure 16. The Top 10 and 5 Players Market Share by Adrenomyeloneuropathy Treatment Revenue in 2020
Figure 17. Global Adrenomyeloneuropathy Treatment Revenue Market Share by Type (2016-2021)
Figure 18. Global Adrenomyeloneuropathy Treatment Revenue Market Share by Type (2022-2027)
Figure 19. North America Adrenomyeloneuropathy Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 20. North America Adrenomyeloneuropathy Treatment Market Share by Type (2016-2027)
Figure 21. North America Adrenomyeloneuropathy Treatment Market Share by Application (2016-2027)
Figure 22. North America Adrenomyeloneuropathy Treatment Market Share by Country (2016-2027)
Figure 23. United States Adrenomyeloneuropathy Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 24. Canada Adrenomyeloneuropathy Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Europe Adrenomyeloneuropathy Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Europe Adrenomyeloneuropathy Treatment Market Share by Type (2016-2027)
Figure 27. Europe Adrenomyeloneuropathy Treatment Market Share by Application (2016-2027)
Figure 28. Europe Adrenomyeloneuropathy Treatment Market Share by Country (2016-2027)
Figure 29. Germany Adrenomyeloneuropathy Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 30. France Adrenomyeloneuropathy Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. U.K. Adrenomyeloneuropathy Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. Italy Adrenomyeloneuropathy Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Russia Adrenomyeloneuropathy Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Nordic Adrenomyeloneuropathy Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Asia-Pacific Adrenomyeloneuropathy Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Asia-Pacific Adrenomyeloneuropathy Treatment Market Share by Type (2016-2027)
Figure 37. Asia-Pacific Adrenomyeloneuropathy Treatment Market Share by Application (2016-2027)
Figure 38. Asia-Pacific Adrenomyeloneuropathy Treatment Market Share by Region (2016-2027)
Figure 39. China Adrenomyeloneuropathy Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. Japan Adrenomyeloneuropathy Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. South Korea Adrenomyeloneuropathy Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. Southeast Asia Adrenomyeloneuropathy Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. India Adrenomyeloneuropathy Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Australia Adrenomyeloneuropathy Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Latin America Adrenomyeloneuropathy Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Latin America Adrenomyeloneuropathy Treatment Market Share by Type (2016-2027)
Figure 47. Latin America Adrenomyeloneuropathy Treatment Market Share by Application (2016-2027)
Figure 48. Latin America Adrenomyeloneuropathy Treatment Market Share by Country (2016-2027)
Figure 49. Mexico Adrenomyeloneuropathy Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Brazil Adrenomyeloneuropathy Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Middle East & Africa Adrenomyeloneuropathy Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Middle East & Africa Adrenomyeloneuropathy Treatment Market Share by Type (2016-2027)
Figure 53. Middle East & Africa Adrenomyeloneuropathy Treatment Market Share by Application (2016-2027)
Figure 54. Middle East & Africa Adrenomyeloneuropathy Treatment Market Share by Country (2016-2027)
Figure 55. Turkey Adrenomyeloneuropathy Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 56. Saudi Arabia Adrenomyeloneuropathy Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. UAE Adrenomyeloneuropathy Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. Ascend Biopharmaceuticals Revenue Growth Rate in Adrenomyeloneuropathy Treatment Business (2016-2021)
Figure 59. Novadip Biosciences Revenue Growth Rate in Adrenomyeloneuropathy Treatment Business (2016-2021)
Figure 60. Eureka Therapeutics Revenue Growth Rate in Adrenomyeloneuropathy Treatment Business (2016-2021)
Figure 61. Human Longevity Revenue Growth Rate in Adrenomyeloneuropathy Treatment Business (2016-2021)
Figure 62. Regeneus Revenue Growth Rate in Adrenomyeloneuropathy Treatment Business (2016-2021)
Figure 63. Allogene Therapeutics Revenue Growth Rate in Adrenomyeloneuropathy Treatment Business (2016-2021)
Figure 64. BioRestorative Therapies Revenue Growth Rate in Adrenomyeloneuropathy Treatment Business (2016-2021)
Figure 65. Immatics Biotechnologies Revenue Growth Rate in Adrenomyeloneuropathy Treatment Business (2016-2021)
Figure 66. NewLink Genetics Revenue Growth Rate in Adrenomyeloneuropathy Treatment Business (2016-2021)
Figure 67. Cytori Therapeutics Revenue Growth Rate in Adrenomyeloneuropathy Treatment Business (2016-2021)
Figure 68. Talaris Therapeutics Revenue Growth Rate in Adrenomyeloneuropathy Treatment Business (2016-2021)
Figure 69. Bottom-up and Top-down Approaches for This Report
Figure 70. Data Triangulation
Figure 71. Key Executives Interviewed

以下、関連資料のご紹介

世界の色汗症治療市場規模・現状・予測（2021年-2027年）

Global Chromhidrosis Treatment Market Size, Status and Forecast 2021-2027
QFJ1-5658 2021年6月 88Pages
QYResearch社発行の本調査レポートでは、色汗症治療の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（アポクリン色汗症、エクリン色汗症、偽色汗症）、用途別市場規模（病院＆診療所、専門医＆皮膚科医院、その他）、主要地域別市場規模（北米、アメリカ、...

世界の人工関節感染症治療市場規模・現状・予測（2021年-2027年）

Global Prosthetic Joint Infections Treatment Market Size, Status and Forecast 2021-2027
QFJ1-4776 2021年6月 98Pages
QYResearch社発行の本調査レポートでは、人工関節感染症治療の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（フシジン酸、酢酸レファムリン、MTF-101、TNP-2092、その他）、用途別市場規模（病院、クリニック、その他）、主要地域別市場規...

世界の肝腎症候群治療市場規模・現状・予測（2021年-2027年）

Global Hepatorenal Syndrome Treatment Market Size, Status and Forecast 2021-2027
QFJ1-4305 2021年6月 88Pages
QYResearch社発行の本調査レポートでは、肝腎症候群治療の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（ヘパトレン、テルリバズ、グリプレシン、ルカシン、その他）、用途別市場規模（1型肝腎症候群、2型肝腎症候群）、主要地域別市場規模（北米、アメ...

世界の多汗症治療市場規模・現状・予測（2021年-2027年）

Global Hyperhidrosis Treatment Market Size, Status and Forecast 2021-2027
QFJ1-4337 2021年6月 99Pages
QYResearch社発行の本調査レポートでは、多汗症治療の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（投薬、外科治療、理学療法、その他）、用途別市場規模（病院、皮膚科、その他）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国...

世界のバッテン病治療市場規模・現状・予測（2021年-2027年）

Global Batten Disease Treatment Market Size, Status and Forecast 2021-2027
QFJ1-3891 2021年6月 96Pages
QYResearch社発行の本調査レポートでは、バッテン病治療の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（作業療法、理学療法）、用途別市場規模（乳児NCL、後期乳児NCL、少年NCL、成人NCL）、主要地域別市場規模（北米、アメリカ、欧州、アジ...

世界のリーシュマニア症治療市場規模・現状・予測（2021年-2027年）

Global Leishmaniasis Treatment Market Size, Status and Forecast 2021-2027
QFJ1-4421 2021年6月 95Pages
QYResearch社発行の本調査レポートでは、リーシュマニア症治療の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（アンチモン酸メグルミン、ペンタミジン、ヒドロキシアミジンスチルベン、アムホテリシンB）、用途別市場規模（内臓リーシュマニア症、皮膚リ...

世界のピーナッツアレルギー治療市場規模・現状・予測（2021年-2027年）

Global Peanut Allergy Treatment Market Size, Status and Forecast 2021-2027
QFJ1-5934 2021年6月 98Pages
QYResearch社発行の本調査レポートでは、ピーナッツアレルギー治療の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（経口、注射可能）、用途別市場規模（小売薬局、病院薬局、オンライン薬局、ドラッグストア、その他）、主要地域別市場規模（北米、アメリ...

世界の手掌多汗症治療市場規模・現状・予測（2021年-2027年）

Global Palmer Hyperhidrosis Treatment Market Size, Status and Forecast 2021-2027
QFJ1-4648 2021年6月 99Pages
QYResearch社発行の本調査レポートでは、手掌多汗症治療の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（医薬品、外科治療、理学療法、その他）、用途別市場規模（原発性限局性多汗症、続発性全身性多汗症）、主要地域別市場規模（北米、アメリカ、欧州、...

世界の尿素サイクル異常症（UCD）治療市場規模・現状・予測（2021年-2027年）

Global Urea Cycle Disorders (UCD) Treatment Market Size, Status and Forecast 2021-2027
QFJ1-5000 2021年6月 88Pages
QYResearch社発行の本調査レポートでは、尿素サイクル異常症（UCD）治療の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（アミノ酸式、フェニル酪酸、安息香酸ナトリウム、その他）、用途別市場規模（病院薬局、小売薬局、オンライン薬局）、主要地域別...

世界のすくみ足症用治療市場規模・現状・予測（2021年-2027年）

Global Freezing of Gait Treatment Market Size, Status and Forecast 2021-2027
QFJ1-4237 2021年6月 97Pages
QYResearch社発行の本調査レポートでは、すくみ足症用治療の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（経口ドーパミン作動薬、ウェアラブル＆歩行補助装置、脳深部刺激療法、その他）、用途別市場規模（病院、診療所、研究所＆学術機関）、主要地域別...

世界の皮膚B細胞リンパ腫治療市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Cutaneous B-Cell Lymphoma Treatment Market The global Cutaneous B-Cell Lymphoma Treatment market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027. With industry-standard accuracy in analysis and hig…
世界のT細胞リンパ腫治療市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global T-Cell Lymphoma Treatment Market The global T-Cell Lymphoma Treatment market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027. With industry-standard accuracy in analysis and high data integrity, th…
世界のリソソーム蓄積症治療市場規模・現状・予測（2021年-2027年） Lysosomal storage disease (LTD) is caused by defect in lysosomal functions and degradation pathway. It is caused by progressive accumulation of metabolites. LTD is a rare inherited metabolic disorder. Market Analysis and Insights: Global Lysosomal Storage Disease Treatment Market The global Lysosoma…
世界のB細胞非ホジキンリンパ腫（NHL）治療市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global B-Cell Non-Hodgkin's Lymphoma (NHL) Treatment Market The global B-Cell Non-Hodgkin's Lymphoma (NHL) Treatment market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027. With industry-standard accuracy…
世界の胎盤幹細胞療法市場規模・現状・予測（2021年-2027年） Placental stem cells are cells derived from the placental blood and other body fluids of a new-born baby. Stem cells are human cells classified into a different variety of cell types, including brain and muscle cells. Stem cells are sometimes used in the development of regenerative therapies. Regene…